Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients

被引:149
作者
Raffa, Monia [2 ]
Mechri, Anwar [1 ,3 ]
Ben Othman, Leila [2 ]
Fendri, Chiraz [1 ,3 ]
Gaha, Lotfi [1 ,3 ]
Kerkeni, Abdelhamid [2 ]
机构
[1] Univ Monastir, Fac Med, Res Lab Vulnerabil Psychot Disorders, Monastir 5000, Tunisia
[2] Univ Monastir, Fac Med, Dept Biophys, Res Lab Trace Elements, Monastir 5000, Tunisia
[3] Univ Hosp Monastir, Dept Psychiat, Monastir 5000, Tunisia
关键词
Antioxidant enzymes; Glutathione; Neuroleptic treatments; Oxidative stress; Schizophrenia; MEMBRANE-LIPID PEROXIDATION; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; THERAPEUTIC IMPLICATIONS; DEFENSE SYSTEM; RAT-BRAIN; ANTIPSYCHOTICS; DOPAMINE; BLOOD; INVOLVEMENT;
D O I
10.1016/j.pnpbp.2009.06.018
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
There is substantial evidence found in the literature that supports the fact that the presence of oxidative stress may play an important role in the physiopathology of schizophrenia. Previous studies have reported the occurrence of impairments in the glutathione levels and the activities of the antioxidant enzymes in patients suffering from schizophrenia. However, most of these studies were performed on treated patients. The present study evaluated treated schizophrenic patients (n = 52) along with neuroleptic-free or untreated schizophrenic patients (n = 36) and healthy controls (n = 46). The blood glutathione levels: total glutathione (GSHt), reduced glutathione (GSHr), and oxidized glutathione (GSSG) as well as the activities of the antioxidant enzymes: superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) were measured. The psychopathology of the patients was assessed through the Clinical Global Impressions-severity (CGI-severity). The tests revealed that in comparison with the healthy controls, the schizophrenic patients showed significantly lower levels of GSHr, SOD, and CAT. Among the schizophrenic patients, the activities of the antioxidant enzymes SOD and CAT were recorded to be significantly lower in untreated patients than in the treated ones. In addition, the levels of both GSHt and GSHr were found to be inversely correlated with the obtained CGI-severity score. These results evidently suggest that a decrease in the glutathione levels and the activities of the antioxidant enzymes in patients diagnosed with schizophrenia is not related to neuroleptic treatment and could be considered as a biological indicator of the degree of severity of the symptoms of schizophrenia. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:1178 / 1183
页数:6
相关论文
共 35 条
[1]
Akerboom T., 1981, METHOD ENZYMOL, P373
[2]
The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients The possible role of oxidant/antioxidant imbalance [J].
Akyol, Ö ;
Herken, H ;
Uz, E ;
Fadillioglu, E ;
Ünal, S ;
Sögüt, S ;
Özyurt, H ;
Savas, HA .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (05) :995-1005
[3]
Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients [J].
Altuntas, I ;
Aksoy, H ;
Coskun, I ;
Çayköylü, A ;
Akçay, F .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (12) :1277-1281
[4]
[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
[5]
BEERS RF, 1952, J BIOL CHEM, V195, P133
[6]
Altered antioxidant defense system in clinidcally stable patients with schizophrenia and their unaffected siblings [J].
Ben Othmen, Leila ;
Mechri, Anwar ;
Fendri, Chiraz ;
Bost, Muriel ;
Chazot, Guy ;
Gaha, Lotfi ;
Kerkeni, Abdelhamid .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (01) :155-159
[7]
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial [J].
Berk, Michael ;
Copolov, David ;
Dean, Olivia ;
Lu, Kristy ;
Jeavons, Sue ;
Schapkaitz, Ian ;
Anderson-Hunt, Murray ;
Judd, Fiona ;
Katz, Fiona ;
Katz, Paul ;
Ording-Jespersen, Sean ;
Little, John ;
Conus, Philippe ;
Cuenod, Michel ;
Do, Kim Q. ;
Bush, Ashley I. .
BIOLOGICAL PSYCHIATRY, 2008, 64 (05) :361-368
[8]
Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence [J].
Carlsson, A ;
Waters, N ;
Holm-Waters, S ;
Tedroff, J ;
Nilsson, M ;
Carlsson, ML .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :237-260
[9]
Schizophrenia:: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo [J].
Do, KQ ;
Trabesinger, AH ;
Kirsten-Krüger, M ;
Lauer, CJ ;
Dydak, U ;
Hell, D ;
Holsboer, F ;
Boesiger, P ;
Cuénod, M .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (10) :3721-3728
[10]
Fendri C, 2006, ENCEPHALE, V32, P244